Last update 22 Mar 2025

Respiratory Syncytial Virus Vaccine(Moderna)

Overview

Basic Info

Drug Type
Prophylactic vaccine, mRNA vaccine
Synonyms
Respiratory Syncytial Virus (RSV) pre-fusion F protein (Moderna), Respiratory syncytial virus (RSV) vaccine (Moderna), mRNA 1345
+ [2]
Action
modulators
Mechanism
Respiratory syncytial virus F protein modulators(Respiratory syncytial virus F protein modulators)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
European Union (22 Aug 2024),
RegulationFast Track (United States), Priority Review (Australia), Breakthrough Therapy (United States)
Login to view timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Respiratory Syncytial Virus Infections
European Union
23 Aug 2024
Respiratory Syncytial Virus Infections
Iceland
23 Aug 2024
Respiratory Syncytial Virus Infections
Liechtenstein
23 Aug 2024
Respiratory Syncytial Virus Infections
Norway
23 Aug 2024
Pneumonia due to respiratory syncytial virus
European Union
22 Aug 2024
Pneumonia due to respiratory syncytial virus
Iceland
22 Aug 2024
Pneumonia due to respiratory syncytial virus
Liechtenstein
22 Aug 2024
Pneumonia due to respiratory syncytial virus
Norway
22 Aug 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Influenza, HumanPhase 3
United States
01 Apr 2022
Severe Acute Respiratory SyndromePhase 3
United States
01 Apr 2022
Human Metapneumovirus InfectionPhase 1
United States
15 Feb 2023
Human Metapneumovirus InfectionPhase 1
Australia
15 Feb 2023
Human Metapneumovirus InfectionPhase 1
Canada
15 Feb 2023
Human Metapneumovirus InfectionPhase 1
Panama
15 Feb 2023
Human Metapneumovirus InfectionPhase 1
Poland
15 Feb 2023
Human Metapneumovirus InfectionPhase 1
South Africa
15 Feb 2023
Human Metapneumovirus InfectionPhase 1
Spain
15 Feb 2023
Human Metapneumovirus InfectionPhase 1
United Kingdom
15 Feb 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2/3
35,541
iixwfrwomj(eyqfrtusjm) = noznpzityc zumnwqsmrp (aoqeuhoxob, 66.0 - 92.2)
Positive
14 Dec 2023
Placebo
ezfurptrbb(dlgjaerijk) = zmaxrfbqyu gpjaxzzfmb (glxsgromsu )
Phase 3
37,000
zweskvipcw(fjinqjpfxl) = fyfugaxjvz rwivodawdi (jccrmrlpyl, 66.1 - 92.2)
Positive
03 Aug 2023
Phase 3
37,000
jslmgqeyhc(bvnaxkwojw) = wmbijuiuij cbjigutzbp (tduhnvfwqy )
Met
Positive
17 Jan 2023
Placebo
jslmgqeyhc(bvnaxkwojw) = poukcvbrfl cbjigutzbp (tduhnvfwqy )
Met
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free